MedTrace Logo

Effects of CBD/CBD-A Oral Extract on Resting-state EEG and Neuropathic Pain Symptoms After SCI

NCT05630235 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-06-17

No results posted yet for this study

Summary

The main purposes of this study are to (1) measure the effect of CBD/CBD-A on pain symptoms, pain intensity, pain unpleasantness, and skin sensitivity to hot and cold temperatures; and (2) measure the effect of CBD on brain electrical activity with electroencephalography (EEG).

Conditions

  • SCI - Spinal Cord Injury
  • Neuropathic Pain

Interventions

DRUG

CBD/CBD-A

Participants will be administered a one-time dose of 204.6 mg of CBD/CBD-A orally.

OTHER

Placebo

The placebo equivalent of the CBD/CBD-A dose administered orally.

Sponsors & Collaborators

  • Consortium for Medical Marijuana Clinical Outcomes Research

    collaborator OTHER

  • University of Miami

    lead OTHER

Principal Investigators

  • Eva Widerstrom-Noga, PhD, DDS · University of Miami

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-16
Primary Completion
2026-06-30
Completion
2026-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05630235 on ClinicalTrials.gov